3rd Quarter - Report — DELAHUNT GROUP, LLC for HEALIANCE PHARMACEUTICALS (2013)

Firm

DELAHUNT GROUP, LLC

Client

HEALIANCE PHARMACEUTICALS

Income

$45,000

Expenses

—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

innovative diabetes treatment.

Foreign entity interest: foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

Lobbyist	Covered position, as disclosed
WILLIAM DELAHUNT	Member of the U.S. House of Representatives

Contacted: Treasury, Dept of; SENATE; Natl Security Agency (NSA); HOUSE OF REPRESENTATIVES; State, Dept of (DOS)

Foreign Relations FOR

innovative diabetes treatment

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

Lobbyist	Covered position, as disclosed
WILLIAM DELAHUNT	Member of the U.S. House of Representatives

Contacted: HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Treasury, Dept of; SENATE; Natl Security Agency (NSA)

Pharmacy PHA

innovative diabetes treatment.

Foreign entity interest: foreign entity Digen Pharmaceuticals will benefit from FDA approval of the product.

Lobbyist	Covered position, as disclosed
WILLIAM DELAHUNT	Member of the U.S. House of Representatives

Contacted: State, Dept of (DOS); HOUSE OF REPRESENTATIVES; Treasury, Dept of; Natl Security Agency (NSA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.